DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Friday morning. The firm issued a hold rating on the stock.

Other equities analysts have also issued reports about the stock. HC Wainwright reaffirmed a buy rating and set a $5.00 target price on shares of DBV Technologies in a research report on Thursday, August 1st. JMP Securities restated a market outperform rating and set a $5.00 price objective on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Price Performance

DBVT opened at $0.70 on Friday. The business has a fifty day moving average of $0.86 and a 200 day moving average of $1.06. The stock has a market cap of $67.55 million, a P/E ratio of -0.83 and a beta of 0.68. DBV Technologies has a 52-week low of $0.50 and a 52-week high of $2.74.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The company had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. During the same period in the prior year, the firm posted ($0.26) earnings per share. Equities analysts anticipate that DBV Technologies will post -1.43 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. boosted its position in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies makes up approximately 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.